Whittier Trust Co. of Nevada Inc. Has $8.62 Million Stock Position in IQVIA Holdings Inc. $IQV

Whittier Trust Co. of Nevada Inc. raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 54,680 shares of the medical research company’s stock after purchasing an additional 1,076 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in IQVIA were worth $8,617,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Mather Group LLC. boosted its holdings in IQVIA by 83.5% during the first quarter. Mather Group LLC. now owns 769 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 350 shares in the last quarter. Patton Fund Management Inc. acquired a new stake in IQVIA during the second quarter valued at approximately $231,000. Verdence Capital Advisors LLC acquired a new stake in IQVIA during the second quarter valued at approximately $3,612,000. Private Advisor Group LLC raised its stake in shares of IQVIA by 11.6% in the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock valued at $958,000 after acquiring an additional 566 shares during the last quarter. Finally, Raleigh Capital Management Inc. raised its stake in shares of IQVIA by 85.5% in the second quarter. Raleigh Capital Management Inc. now owns 3,350 shares of the medical research company’s stock valued at $528,000 after acquiring an additional 1,544 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

IQV stock opened at $212.30 on Tuesday. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The company has a 50 day moving average price of $192.05 and a 200 day moving average price of $169.60. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $235.32. The stock has a market capitalization of $36.09 billion, a PE ratio of 30.72, a price-to-earnings-growth ratio of 2.25 and a beta of 1.32.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion during the quarter, compared to analysts’ expectations of $3.96 billion. During the same quarter in the previous year, the company posted $2.64 EPS. IQVIA’s revenue was up 5.3% on a year-over-year basis. Analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company’s stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares of the company’s stock, valued at $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on IQV shares. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Truist Financial lifted their target price on shares of IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. Evercore ISI lifted their target price on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research note on Wednesday, October 8th. UBS Group lifted their target price on shares of IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. Finally, HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and lifted their target price for the company from $195.00 to $235.00 in a research note on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average target price of $234.57.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.